Search

Displaying results 61 - 70 of 13621 in total
  1. Target

    Tyrosine-protein kinase JAK2

    go.drugbank.com/bio_entities/BE0002408
    TargetHumans

    Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. … Binding of CNTF or the CLCF1/CLF heterodimer to CNTFR leads to IL6ST/gp130-LIFR dimerization followed by activation of JAK1 and JAK2 which in turns phosphorylate IL6ST/gp130 and LIFR (PubMed:11294841).

    Polypeptides: Tyrosine-protein kinase JAK2Synonyms: JAK-2
  2. Target

    Tyrosine-protein kinase JAK1

    go.drugbank.com/bio_entities/BE0004145
    TargetHumans

    Binding of CNTF or the CLCF1/CLF heterodimer to CNTFR leads to IL6ST/gp130-LIFR dimerization followed by activation of JAK1 and JAK2 which in turns phosphorylate IL6ST/gp130 and LIFR (PubMed:11294841). … Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors (PubMed:16239216, PubMed:32750333, PubMed:8232552

    Polypeptides: Tyrosine-protein kinase JAK1Synonyms: JAK-1
  3. Drug

    Diclofenac

    go.drugbank.com/drugs/DB00586
    ApprovedInvestigationalVet approved

    Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID). … Diclofenac, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammation from a variety of causes.

    Mixtures: DermacinRx Lexitral PharmaPak II, Diclo Gel 1% PakCategories: Cyclooxygenase-2 (COX-2) Inhibitors, P-glycoprotein inducers
  4. Drug

    Albuterol

    go.drugbank.com/drugs/DB01001
    ApprovedInvestigationalVet approved

    Salbutamol is formulated as a racemic mixture of the R- and S-isomers. … The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity.

    Mixtures: UNIBRON R, Salmodil-SF Expectorant SyrupCategories: Adrenergic beta-2 Receptor Agonists, Cytochrome P-450 CYP3A Inhibitors
  5. Drug

    Levocetirizine

    go.drugbank.com/drugs/DB06282
    ApprovedInvestigational

    Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. … [L7694] Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]

    Mixtures: ANTISS® D, ANTISS® DCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Interferon alfa-2a

    go.drugbank.com/drugs/DB00034
    ApprovedInvestigationalWithdrawn

    Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. … An oral form is being developed by Amarillo Biosciences.

    Categories: Interferon Type I, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: SH-polypeptide-46
  7. Drug

    Glecirasib

    go.drugbank.com/drugs/DB18744
    Investigational

    Synonyms: JAB-21822
  8. Drug

    Indapamide

    go.drugbank.com/drugs/DB00808
    ApprovedInvestigational

    [A204134,A204161] Indapamide is characterized by both a methylindoline and a sulfamoyl chlorobenzamide functional group, with the former being largely responsible for the molecule’s lipid solubility … The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension.

    Mixtures: PERDUO 4/1.5 MG SR FILM KAPLI TABLET, 30 ADET, PERDUO 4/1.5 MG SR FILM KAPLI TABLET, 90 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Upadacitinib

    go.drugbank.com/drugs/DB15091
    ApprovedInvestigational

    [A189171] The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid … Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  10. Drug

    St. John's Wort

    go.drugbank.com/drugs/DB01323
    ApprovedNutraceutical

    Mixtures: S. R. FormulaCategories: P-glycoprotein inducers, Cytochrome P-450 Substrates